Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244457 | 0.86 | CYP2C19 (0.39) | NPSR1CYP4F2CYP4A11LMNACYP2C19 | |
| SCHEMBL15125183 | 0.84 | NPSR1 (0.38) | NPSR1CYP4F2CYP4A11LMNAOPRM1 | |
| SCHEMBL12462298 | 0.82 | NPSR1 (0.46) | NPSR1CYP4F2CYP4A11LMNACYP2C19 | |
| SCHEMBL225044 | 0.82 | NPSR1 (0.46) | NPSR1CYP4F2CYP4A11LMNACYP2C19 | |
| SCHEMBL6059836 | 0.80 | TSHR (0.36) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL374026 | 0.80 | ALDH1A1 (0.46) | LMNATRPA1ALDH1A1OPRM1MAPT | |
| SCHEMBL6059827 | 0.77 | ALDH1A1 (0.40) | NPSR1CYP4F2CYP4A11ALDH1A1TSHR | |
| SCHEMBL14995506 | 0.76 | NPSR1 (0.33) | NPSR1CYP4F2CYP4A11CYP2C19 | |
| SCHEMBL3606720 | 0.75 | NPSR1 (0.41) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL71320 | 0.75 | NPSR1 (0.41) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | disclosed |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3911652-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | Biogen MA Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-3652177-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2020-05-20 | — | — | EP | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| CN-110997678-A | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | CHKA, CHKB, NADK | NPSR1 4537/4885CYP4F2 3224/4885CYP4A11 3159/4885 |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | CHKA, CHKB, NADK | NPSR1 4581/4885CYP4F2 2529/4885CYP4A11 2468/4885 |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | NPSR1 4196/4885CYP4F2 2194/4885CYP4A11 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.